NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) PHAT on behalf of Phathom shareholders. Our investigation concerns whether Phathom has violated federal securities laws and/or engaged in other illegal business practices.

Click Here to take part in the action.

On August 2, 2022, prior to market close, Phathom issued a press release titled, “Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates,” announcing that “in our post-market approval, we have identified trace amounts of a nitrosamine in the vonoprazan drug product.” have found.” testing as we prepared for commercial launch. In addition, the press release said: “[t]The Company is working with the FDA and plans to approve and implement an additional test method, specification, including a proposed acceptable intake limit and additional controls, to eliminate this impurity before we commercialize our first oprazan-based products.” Finally, the Company announced known that “[t]These additional activities will result in a delay of the planned VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK product launches.”

As a result of this news, Phathom’s stock price fell $2.61 per share, or 28%, to close at $6.46 per share on August 2, 2022.

If you have purchased or otherwise acquired Phathom stock and have suffered a loss, are a long-standing shareholder, have information, would like to learn more about these claims, or have any questions about this announcement or your rights or interests in relation to these matters, please contact us Email them Brandon Walker or Melissa Fortunato at investigatives@bespc.comby phone at (212) 355-4648 or by Fill out this contact form. There are no costs or obligations for you.

About Bragar Eagle & Squire, PC:

Bragar Eagel & Squire, PC is a nationally recognized law firm with offices in New York and…